Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 144-150

  Nannini, Margherita ^a   Biasco, Guido ^a,b   Pallotti, Maria Caterina ^a   Di Battista, Monica ^a   Santini, Donatella ^a   Paterini, Paola ^b   Maleddu, Alessandra ^a   Mandrioli, Anna ^a   Lolli, Cristian ^a   Saponara, Maristella ^a   Di Scioscio, Valerio ^a   Zompatori, Maurizio ^a   Catena, Fausto ^a   Fusaroli, Pietro ^b   Dei Tos, Angelo Paolo ^c   Pantaleo, Maria Abbondanza ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c General Hospital of Treviso   (Italy)

Author keywords

Follow up; GIST; Late recurrences; Mutational analysis; Risk stratification

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER; MALE; PERITONEUM; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR LOCALIZATION; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84864032354     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9806-7     Document Type: Article

References (33)

1. Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347:472-80. (Pubitemid 34879334)
2. Demetri GD, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368: 1329-38. (Pubitemid 44528723)
3. Dematteo RP, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097-104.
4. Debiec-Rychter M, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer; 42:1093-103.
5. Heinrich MC, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352-9.
6. Pantaleo MA, et al. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer. 2009;125:2991-4.
7. Choi H, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesy-late: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-9. (Pubitemid 46797957)
8. Demetri GD, et al. National comprehensive cancer network. Soft tissue sarcoma. J Natl Compr Canc Netw. 2007;5(4):364-99 (Version 2.2010).
9. Casali PG, Blay JY, On behalf of the ESMO/CONTICANET/EUROBONET consensus panel of experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v98-v102 (Suppl 5).
10. Dematteo RP, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112:608-15.
11. Fletcher CD, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-65. (Pubitemid 34747864)
12. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23:70-83. (Pubitemid 44692418)
13. Corless CL, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol. 2010;28:7 s (suppl; abstr 10006).
14. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010 Epub ahead of print.
15. Almog N, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 2009;69:836-44.
16. Meltzer A. Dormancy and breast cancer. J Surg Oncol. 1990;43: 181-8. (Pubitemid 20096307)
17. Karrison T, Ferguson D, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91:80-5. (Pubitemid 29042447)
18. Willis L, et al. Breast cancer dormancy can be maintained by small numbers of micrometastases. Cancer Res. 2010;70:4310-7.
19. Ossowski L, Aguirre-Ghiso JA. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res. 2010;23:41-56.
20. Hansel G, Schönlebe J, Haroske G, Wollina U. Late recurrence (10 years or more) of malignant melanoma in south-east Germany (Saxony) A single-centre analysis of 1881 patients with a follow-up of 10 years or more. J Eur Acad Dermatol Venereol 2010 Epub ahead of print.
21. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer. 1997;79:2361-70. (Pubitemid 27251019)
22. Agaimy A, Wünsch PH. Sporadic Cajal cell hyperplasia is common in resection specimens for distal oesophageal carcinoma. A retrospective review of 77 consecutive surgical resection specimens. Virchows Arch. 2006;448:288-94. (Pubitemid 43357644)
23. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 2002;160: 1567-72. (Pubitemid 34525636)
24. Agaimy A, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007;31:113-20. (Pubitemid 46036910)
25. Agaimy A, et al. Multiple sporadic gastrointestinal stromal tumors (GISTs) of the proximal stomach are caused by different somatic KIT mutations suggesting a field effect. Am J Surg Pathol. 2008;32:1553-9.
26. Gasparotto D, et al. Multiple primary sporadic gastrointestinal stromal tumors in the adult: an underestimated entity. Clin Cancer Res. 2008;14:5715-21.
27. Haller F, et al. Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis. Am J Surg Pathol. 2007;31:933-7. (Pubitemid 47165149)
28. Kang DY, et al. Multiple gastrointestinal stromal tumors: clini-copathologic and genetic analysis of 12 cases. Am J Surg Pathol. 2007;31:224-32. (Pubitemid 46175023)
29. Bouvier AM, et al. The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up. Eur J Cancer. 2008;44:522-7.
30. Bradford PT, et al. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol. 2010;146:265-72.
31. Parker RG, Grimm P, Enstrom JE. Contralateral breast cancers following treatment for initial breast cancers in women. Am J Clin Oncol. 1989;12:213-6. (Pubitemid 19156447)
32. Agaimy A, et al. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol. 2006; 23:120-9. (Pubitemid 44692421)
33. Ponti G, et al. Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting. Oncol Rep. 2010;23:437-44.